Currently, the MyoRegulator® device is under investigation as a non-invasive treatment for ALS in a second and larger clinical trial, the CALM ( C ontrolling A myotrophic L ateral Sclerosis M otor ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

The FDA has granted fast track designation to a vectorized antibody that targets RNA-binding proteins characteristic of neurodegenerative diseases.According to a press release from VectorY ...

Some evidence reports natural medications, such as Wugongtang and Dihuangyinzi, may help slow the progression of ALS or Lou Gehrig’s disease. However, they cannot cure it. Amyotrophic lateral ...

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, invariably fatal neurological disease. Individuals affected by ALS include those living with ALS, their caregivers, presymptomatic ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ ...

NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...

The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.

This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged ...